Compound Radar

Liquidia Corporation (LQDA) Stock Analysis

Price $67.68
Market cap $6.06B
Next earnings Nov 3, 2026
Entry status Wait

Last updated Sep 8, 2026

Health Check

Last analyzed Sep 7, 2026

45
45/100 Speculative
  • Financial Health 40
  • Profitability 100
  • Business Quality 65
  • Balance Sheet 65
  • Cash Flow 55

Why this rating?

Health 45/100 — Speculative

Strongest Profitability 100/100
Softest Financial Health 40/100
Wait

Entry timing is weak right now. Quality may be fine; the setup is not.

Company overview

Liquidia Corporation (LQDA) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates Liquidia Corporation 45/100 (Speculative) due to solid business quality, strong revenue growth, and elevated leverage.

Investment profile

  • Quality Moderate
  • Growth Strong
  • Balance Sheet Stretched
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 48.34
  • Forward P/E 11.98
  • EV/Revenue 13.41

Profitability

  • Revenue Growth 1842.7%
  • Gross Margin 92.5%
  • Operating Margin 49.8%
  • Net Margin 30.7%
  • ROE 131.8%

Financial strength

  • Cash $284.18M
  • Debt $182.90M
  • Net Cash $101.28M
  • Free Cash Flow $-42.02M
  • Current Ratio 2.31

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks Liquidia Corporation (LQDA).

View Methodology & FAQ →